GlassScriptPhysician profile
Pascual De Santis
NPI 1225156565
$5,656.66
in general payments reported to CMS, 2019-2025
33 companies · $3,875 in 2025
The $3,875 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $116 · 2021: $56.24 · 2022: $238 · 2023: $606 · 2024: $485 · 2025: $3,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Consulting Fee: $2,425 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.03 |
| Consulting Fee | $2,425.00 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,745.56 | 2019-2025 | |
| Lilly USA, LLC | $329.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $326.12 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $298.30 | 2019-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $262.99 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $262.23 | 2022-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $225.07 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $167.77 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $120.03 | 2024-2025 | Isturisa |
| Medtronic, INC. | $104.85 | 2023-2025 | Minimed 780g |
| Dexcom, INC. | $88.38 | 2023-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $63.94 | 2025 | Twiist |
| Corcept Therapeutics | $62.78 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $58.64 | 2025 | |
| Averitas Pharma INC. | $49.87 | 2023-2025 | Qutenza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $45.44 | 2019-2022 | |
| Pfizer INC. | $41.74 | 2023-2025 | |
| Halozyme INC | $41.46 | 2023 | |
| Abbvie INC. | $34.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.39 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $31.72 | 2019 | |
| Esperion Therapeutics, INC. | $27.12 | 2024 | Nexletol |
| Roche Diabetes Care, INC. | $26.74 | 2020 | |
| Ibsa Pharma INC. | $24.34 | 2025 | Flector, Licart, Tirosint |
| Abbott Laboratories | $23.75 | 2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $21.56 | 2021 | |
| Cequr Corporation | $21.05 | 2023 | Cequr Simplicity |
| Beta Bionics, INC. | $19.88 | 2024 | Ilet Bionic Pancreas |
| Valeritas, INC. | $18.02 | 2019 | |
| Companion Medical, INC. | $17.39 | 2019 | |
| Ascensia Diabetes Care US INC. | $15.18 | 2024 | |
| Senseonics, Incorporated | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascual De Santis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.